scispace - formally typeset
D

David R. Soto-Pantoja

Researcher at Wake Forest University

Publications -  69
Citations -  7366

David R. Soto-Pantoja is an academic researcher from Wake Forest University. The author has contributed to research in topics: Medicine & Cancer. The author has an hindex of 24, co-authored 50 publications receiving 6427 citations. Previous affiliations of David R. Soto-Pantoja include National Institutes of Health.

Papers
More filters
Journal ArticleDOI

Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition)

Daniel J. Klionsky, +2522 more
- 21 Jan 2016 - 
TL;DR: In this paper, the authors present a set of guidelines for the selection and interpretation of methods for use by investigators who aim to examine macro-autophagy and related processes, as well as for reviewers who need to provide realistic and reasonable critiques of papers that are focused on these processes.
Journal ArticleDOI

CD47 in the tumor microenvironment limits cooperation between antitumor T-cell immunity and radiotherapy.

David R. Soto-Pantoja, +7 more
- 01 Dec 2014 - 
TL;DR: It is reported that blocking CD47 in the context of radiotherapy enhances antitumor immunity by directly stimulating CD8(+) cytotoxic T cells, with the potential to increase curative responses.
Journal ArticleDOI

Radioprotection in normal tissue and delayed tumor growth by blockade of CD47 signaling.

Justin B. Maxhimer, +9 more
- 21 Oct 2009 - 
TL;DR: Combined treatment of high-dose radiation and CD47 suppression in these translational studies suggests that a more aggressive therapeutic irradiation strategy with concurrent protection of neighboring normal tissue is possible.
Journal ArticleDOI

Angiotensin-(1-7) Inhibits Growth of Human Lung Adenocarcinoma Xenografts in Nude Mice through a Reduction in Cyclooxygenase-2

Jyotsana Menon, +6 more
- 15 Mar 2007 - 
TL;DR: The results suggest that Ang-(1-7) may decrease COX-2 activity and proinflammatory prostaglandins to inhibit lung tumor growth and suggest that the heptapeptide represents a novel treatment for lung cancer by reducing COx-2.
Journal ArticleDOI

Angiotensin-(1-7) inhibits tumor angiogenesis in human lung cancer xenografts with a reduction in vascular endothelial growth factor

David R. Soto-Pantoja, +3 more
- 01 Jun 2009 - 
TL;DR: The results suggest that Ang-(1-7) may attenuate tumor angiogenesis by reducing vascular endothelial growth factor-A, a primary proangiogenic protein.